The United Kingdom's National Institute for Health and Care Excellence (NICE) has issued guidance recommending ixazomib (Ninlaro) in for patients with relapsed/refractory multiple myeloma.1
= .02). The median duration of response was 20.5 months with ixazomib versus 15.0 months in the control arm.
- NICE.org/uk. Final appraisal determination: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. https://www.nice.org.uk/guidance/gid-ta10043/documents/html-content-3. Updated December 19, 2017. Accessed December 19, 2017.
- Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621-1634.
... to read the full story